Fundamental Analysis of BENITEC BIOPHARMA INC(NASDAQ:BNTC) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to BNTC. BNTC was compared to 588 industry peers in the Biotechnology industry. While BNTC seems to be doing ok healthwise, there are quite some concerns on its profitability. BNTC has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

BNTC had negative earnings in the past year.

In the past year BNTC has reported a negative cash flow from operations.

BNTC had negative earnings in 4 of the past 5 years.

BNTC had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -102.15%, BNTC is doing worse than 79.15% of the companies in the same industry.

BNTC has a Return On Equity of -141.00%. This is in the lower half of the industry: BNTC underperforms 63.76% of its industry peers.

		Industry Rank	Sector Rank
ROA	-102.15%
ROE	-141%
ROIC	N/A

ROA(3y)-269.5%

ROA(5y)-172.93%

ROE(3y)-3493.89%

ROE(5y)-2108.96%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of BNTC (133.33%) is better than 99.83% of its industry peers.

In the last couple of years the Gross Margin of BNTC has grown nicely.

BNTC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	133.33%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-29.88%

GM growth 5Y2.08%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BNTC does not have a ROIC to compare to the WACC, probably because it is not profitable.

BNTC has more shares outstanding than it did 1 year ago.

BNTC has less shares outstanding than it did 5 years ago.

There is no outstanding debt for BNTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -12.55, we must say that BNTC is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of BNTC (-12.55) is worse than 81.03% of its industry peers.

There is no outstanding debt for BNTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-12.55

ROIC/WACCN/A

WACC9.23%

2.3 Liquidity

A Current Ratio of 3.62 indicates that BNTC has no problem at all paying its short term obligations.

BNTC has a Current ratio of 3.62. This is comparable to the rest of the industry: BNTC outperforms 41.37% of its industry peers.

A Quick Ratio of 3.62 indicates that BNTC has no problem at all paying its short term obligations.

BNTC has a Quick ratio of 3.62. This is comparable to the rest of the industry: BNTC outperforms 42.39% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.62
Quick Ratio	3.62

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BNTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.88%, which is quite impressive.

The Revenue has decreased by 0.00% in the past year.

Measured over the past years, BNTC shows a very negative growth in Revenue. The Revenue has been decreasing by -53.24% on average per year.

EPS 1Y (TTM)61.88%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q22.35%

Revenue 1Y (TTM)0%

Revenue growth 3Y-7.17%

Revenue growth 5Y-53.24%

Revenue growth Q2Q-100%

3.2 Future

BNTC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.86% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y82.22%

EPS Next 2Y35.86%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNTC. In the last year negative earnings were reported.

Also next year BNTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BNTC's earnings are expected to grow with 35.86% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.86%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BNTC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BENITEC BIOPHARMA INC

NASDAQ:BNTC (4/19/2024, 9:20:32 AM)

6.5

-0.32 (-4.69%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap16.84M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-102.15%
ROE	-141%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	133.33%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.62
Quick Ratio	3.62
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)61.88%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y82.22%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)0%

Revenue growth 3Y-7.17%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BENITEC BIOPHARMA INC (BNTC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens